Cancers, Vol. 12, Pages 2864: Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
Cancers, Vol. 12, Pages 2864: Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity Cancers doi: 10.3390/cancers12102864 Authors: Tina Bagratuni Dimitrios Patseas Nefeli Mavrianou-Koutsoukou Christine Ivy Liacos Aimilia D. Sklirou Pantelis Rousakis Maria Gavriatopoulou Evangelos Terpos Ourania E. Tsitsilonis Ioannis P. Trougakos Efstathios Kastritis Meletios A. Dimopoulos Due to increased immunoglobulin production and uncontrolled proliferation, multiple myeloma (MM) plasma cells develop a phenotype of deregulated unfolded protein response (UPR). The eIF2-alpha kinase 3 [EIF2αK3, protein kinase R (PKR)-like ER kinase (PERK)], the third known sensor of endoplasmic reticulum (ER) stress, is a serine-threonine kinase and, like the other two UPR-related proteins, i.e., IRE1 and ATF6, it is bound to the ER membrane. MM, like other tumors showing uncontrolled protein secretion, is highly dependent to UPR for survival; thus, inhibition of PERK can be an effective strategy to suppress growth of malignant plasma cells. Here, we have used GSK2606414, an ATP-competitive potent PERK inhibitor, and found significant anti-proliferative and apoptotic effects in a panel of MM cell lines. These effects were accompanied by the downregulation of key components of the PERK pathway as well as of other UPR elements. Consistently, PERK gene expression silencing significantly increased cell death in MM cells, highlighting the importance of PER...
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
ConclusionMALAT1 is involved in HR pathway by protecting BRCA1 and targeting MALAT1 induces DNA damages in NSCLC.
There is persistent racial disparities in survival among patients with Diffuse Large B Cell Lymphoma. We conducted a cohort study of 181 patients for 10 years in a single community-based inner-city cancer center. Blacks had decreased overall survival compared to non-Blacks even after excluding patients with HIV and who did not receive chemotherapy. R-IPI score alone could not predict worse outcomes and increased mortality in Blacks with DLBCL.
Conclusions Although the laboratory information system’s contribution to the completeness of Cancer Registry incident cases was modest, it is useful to add laboratory data to routine cancer registry information flows due to the increasing use of molecular characterisation and to the phenomenon of dehospitalisation.
Colon perforations are rare in MM and here we report characteristics and clinical outcomes of 30 patients that were treated at Mayo Clinic. We believe that steroids are the precipitating factor. AbstractGastrointestinal complications of multiple myeloma (MM) treatment are common and include nausea, constipation, and diarrhea. However, acute gastrointestinal events like perforations are rare. We aimed to describe the characteristics and outcomes of patients with MM that had colonic perforations during their treatment. This is a retrospective study that included patients from all three Mayo Clinic sites who had MM and develo...
This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1007/s00520-020-05770-w.
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Prajwal Dhakal, Elizabeth Lyden, Kate-Lynn E. Muir, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
ar SK Abstract BACKGROUND: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma (MM), but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in newly diagnosed MM. PATIENTS AND METHODS: This is a retrospective study including 1342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, and who had cytogenetic testing by fluorescence in-situ hybridization at diagnosis, including MYC testing using the break apart FIS...
Blood Cancer Journal, Published online: 02 October 2020; doi:10.1038/s41408-020-00363-6Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
(Stand Up To Cancer) Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to research that focuses on interventions in patients with precursor multiple myeloma, with a particular focus on underserved populations.